Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... on electrons, but one of the most promising technologies ... based on light (photons) instead of electrons. First, it ... of single photons and control their direction. Researchers around ... achieve this control, but now scientists at the Niels ... of photons emitted one at a time and in ...
    (Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
    (Date:8/29/2014)... California (PRWEB) August 29, 2014 ... of Energy's 2014 Hydrogen Production R&D Award ... -- by splitting water using sunlight. , Shared ... (NREL) and the University of Nevada, Las Vegas ... work developing models of photoelectrochemical solar-hydrogen production and ...
    (Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
    Breaking Biology Technology:Breakthrough in light sources for new quantum technology 2Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
    ... cells is limited by a lack of methods for studying ... different methods, a team of Uppsala researchers have now provided ... on several levels at the same time. Their article is ... also show that the method can be used to determine ...
    ... decorative, flower-like defects in the nanomaterial graphene could have ... and mechanical properties, according to researchers at the National ... In a new paper,* the team for the first ... occur naturally or be induced to occur in graphene, ...
    ... of the March 11 earthquake and rolling blackouts that ... award-winning undergraduate internship program NanoJapan is scrambling to run ... U.S. undergraduates travel to Japan for lab internships, NanoJapan ... send 25-30 students to Rice University laboratories for three ...
    Cached Biology Technology:Combo method reveals cells' signal systems 2Defect in graphene may present bouquet of possibilities 2Reverse NanoJapan: Rice to host 25-30 Japanese students 2
    (Date:8/29/2014)... Researchers at UC Davis have made some surprising ... infection. Studying simian immunodeficiency virus (SIV), the team ... Paneth cells are early responders to viral invasion ... producing a cytokine called interleukin-1 beta (IL-1β). ... IL-1β causes breakdown of the gut epithelium that ...
    (Date:8/29/2014)... the University of Texas Medical Branch at Galveston has gone ... can completely protect monkeys against a lethal dose of Ebola ... when the disease is severe. , Thomas Geisbert, professor of ... discussing advances in Ebola treatment research. The filoviruses known ... deadly of pathogens, with fatality rates of up to 90 ...
    (Date:8/29/2014)... available in German . ... the natural nitrogen cycle on Earth and in biological ... thought to depend on nitrite as their source of ... Daims, a microbiologist at the University of Vienna, has ... an alternative source of energy. The oxidation of hydrogen ...
    Breaking Biology News(10 mins):The early cost of HIV 2Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3
    ... nation,s Upper Midwest have changed greatly since the time ... coming. That,s according to research done by Lisa ... of Natural Resource Ecology and Management and her team ... entire ecosystem," said Schulte, whose research has recently been ...
    ... be lacking for perennial wheat to be grown on any ... Dr. Charlie Rush, Texas Agricultural Experiment Station plant pathologist., ... plant breeders, Rush is finding a groundswell of interest as ... on his perennial wheat study., Rush obtained his initial ...
    ... may occur, in part, because of a problem in an ... key chemical messenger in the brain, scientists have found in ... that the gene is turned on at increasingly high rates ... the brain involved in higher functions like thinking and decision-making ...
    Cached Biology News:Upper Midwest forests are losing diversity, complexity, ISU study finds 2A wheat for all seasons -- and reasons 2A wheat for all seasons -- and reasons 3How schizophrenia develops: Major clues discovered 2
    DTT, 25g...
    ...
    ...
    Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
    Biology Products: